Overview

Fuzeon was a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat HIV-1 in combination with other antiretroviral medications. Fuzeon was approved for use in people who are experiencing HIV replication despite ongoing antiretroviral treatment. Fuzeon was also referred to by its drug name, enfuvirtide, and by the abbreviation T-30. 

Fuzeon was an antiviral medication of the fusion inhibitor class. Fuzeon was believed to work by preventing HIV from replicating in cells.

How was it taken?

Prescribing information stated that Fuzeon was taken twice daily by subcutaneous injection. Fuzeon came in vials as a powder.

Side effects

The FDA-approved label for Fuzeon listed common side effects including sleep problems, depression, muscle weakness, fatigue, pain or numbness in the feet and legs, constipation, and pain, irritation, or rash at the injection site.

Rare but serious side effects listed for Fuzeon included hypersensitivity reactions and an increased risk for pneumonia.

For more details about this treatment, visit:

Label: Fuzeon — Enfuvirtide Kit — DailyMed